5-氯-2,4,6-三甲基嘧啶 | 24307-72-0

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 5-氯-2,4,6-三甲基嘧啶
• 英文名称: 5-chloro-2,4,6-trimethyl-pyrimidine
• 英文别名: 5-Chlor-2,4,6-trimethylpyrimidin；5-Chloro-2,4,6-trimethylpyrimidine
• CAS: 24307-72-0
• 化学式: C₇H₉ClN₂
• mdl: MFCD18449387
• 分子量: 156.615
• InChiKey: RGCFSRZOHLLVQS-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.428
• 拓扑面积：
  25.8
• 氢给体数：
  0
• 氢受体数：
  2

安全信息

• 海关编码：
  2933599090

反应信息

• 作为产物：
  描述：

  一氯丙酮 、 乙腈 在 三氟甲磺酸酐 作用下， 以 二氯甲烷 为溶剂， 反应 24.0h， 以86%的产率得到5-氯-2,4,6-三甲基嘧啶
  参考文献：
  名称：

  An Improved Synthesis of 5-Halopyrimidines: Reaction of α-Halo Ketones with Nitriles

  摘要：

  烷基和芳基α-卤甲基酮1在三氟甲磺酸酐存在下与脂肪族和芳香族腈2反应，得到产率良好（55-91%）的取代5-卤吡啶3。

  DOI：

  10.1055/s-1992-26296

文献信息

• Reactions of halogenomethanes in the vapour phase. Part 4. The reactions of imidazoles with chloroform at 550 °C, and a comparison with their liquid-phase reactions with trichloroacetate ion or hexachloroacetone and base
  作者：Reginald E. Busby、Mohammad A. Khan、Mohammad R. Khan、John Parrick、C. J. Granville Shaw、Mohammad Iqbal

  DOI：10.1039/p19800001427

  日期：——

  1-Unsubstituted imidazoles and chloroform at 550 °C in a flow system give mainly 5-chloropyrimidines, together with 4-chloropyrimidines and chloropyrazines. The effects of methyl substituents on the ratio of products is considered. The liquid-phase reactions of 2-methyl- and 2,4,5-trimethyl-imidazole under conditions in which dichlorocarbene is said to be formed in basic or neutral conditions were

  1-未取代的咪唑和氯仿在550°C的流动系统中主要生成5-氯嘧啶，4-氯嘧啶和氯吡嗪。考虑了甲基取代基对产物比例的影响。研究了在碱性或中性条件下形成二氯卡宾的条件下的2-甲基-和2,4,5-三甲基-咪唑的液相反应，并与氯仿的气相反应进行了比较。
• 2-Pyridyl Carboxamide-Containing Spleen Tyrosine Kinase (SYK) Inhibitors
  申请人：MERCK SHARP & DOHME CORP.

  公开号：US20140243336A1

  公开（公告）日：2014-08-28

  The invention provides certain 2-pyridyl carboxamide-containing compounds of the Formula (I) or pharmaceutically acceptable salts thereof, wherein A and B are as defined herein. The invention also provides pharmaceutical compositions comprising such compounds, and methods of using the compounds for treating diseases or conditions mediated by Spleen Tyrosine Kinase (Syk) kinase.

  本发明提供了某些含有2-吡啶基羧酰胺的化合物，其化学式为(I)，或其药学上可接受的盐，其中A和B如本文所定义。本发明还提供了包括这些化合物的药物组合物，并且提供了使用这些化合物治疗由脾脏酪氨酸激酶（Syk）介导的疾病或症状的方法。
• BUSBY R. E.; KHAN M. A.; KHAN M. R.; PARRICK J.; SHAW C. J. G.; IQBAL M., J. CHEM. SOC. PERKIN TRANS., 1980, PART 1 NO 7, 1427-1430
  作者：BUSBY R. E.、 KHAN M. A.、 KHAN M. R.、 PARRICK J.、 SHAW C. J. G.、 IQBAL M.

  DOI：——

  日期：——
• ORGANIC ELECTROLUMINESCENCE ELEMENT, LIGHTING DEVICE AND DISPLAY DEVICE
  申请人：Katakura Rie

  公开号：US20100045171A1

  公开（公告）日：2010-02-25

  Disclosed is an organic electroluminescent device having high external quantum efficiency and long emission life. Also disclosed are an illuminating device and a display, each comprising such an organic electroluminescent device. The organic electroluminescent device is characterized by comprising at least an anode and a cathode on a supporting substrate, while having at least one light-emitting layer between the anode and the cathode. The organic electroluminescent device is also characterized by containing a polymer which at least partially contains a compound A having a partial structure represented by the general formula (a) below and a reactive group, and is obtained by polymerizing the compound A through the reactive group. (In the formula, Ar1 and Ar2 respectively represent an aromatic ring.)
• ORGANIC ELECTROLUMINESCENCE ELEMENT, NEW COMPOUND FOR THE SAME, DISPLAY DEVICE AND LIGHTING DEVICE USING THE SAME
  申请人：KATAKURA Rie

  公开号：US20110006670A1

  公开（公告）日：2011-01-13

  Disclosed is an organic electroluminescence element comprising an anode, a cathode and a plurality of organic compound layers between the anode and the cathode, provided that one of the organic compound layers is a light emitting layer containing a phosphorescence emitting compound, wherein at least one of the organic compound layers contains a compound represented by Formula (1), wherein, X represents O or S; Y 1 to Y 3 each represents a hydrogen atom, a substituent or a group represented by Formula (A) disclosed in the specification, provided that at least two of Y 1 to Y 3 are groups represented by Formula (A), not all of Y 1 to Y 3 are the same group, and at least one of the groups represented by Formula (A) has Ar of a carbazolyl group, or an azacarbazolyl group containing 2 to 5 nitrogen atoms.